Nearly 90 percent of children and adults with a highly aggressive form of acute lymphoblastic leukemia (ALL) showed no evidence of cancer after receiving a novel, personalized cell therapy that reprograms a patient’s immune system. In pilot studies of bioengineered T cells that attack leukemia, 24 of 27 patients (89%) experienced complete responses within 28 days after treatment. In all, 27 patients received the treatment--22 children treated at The Children’s Hospital of Philadelphia and five adults treated at the Hospital of the University of Pennsylvania.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64394-chop-penn-harness-engineered-t-cells-eliminate-tumors-in-blood-leukemia
A ground-breaking retelling and reclaiming of Anne Boleyn’s life and legacy from a preeminent cultural thinker puts old questions to rest and raises some surprising new ones. Learn more about this book http://www.thecreationofanneboleyn.com Historical
Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells to fight leukemia, a research team from the Perelman School of Medicine at the University of Pennsylvania and the Children’s Hospital of Philadelphia will today announce the latest results of studies involving both adults and children with advanced blood cancers that have failed to respond to standard therapies. The findings from the first 59 patients who received this investigational, personalized cellular therapy, known as CTL019, will be presented during the American Society of Hematology’s Annual Meeting and Exposition in New Orleans.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64691-penn-medicine-reports-research-leukemia-patients-cellular-therapy-ctl019
Subaru of America, Inc. and Center for Pet Safety (CPS), a registered 501(c)(3) non-profit research and consumer advocacy organization, announced today the results of the 2015 Crate and Carrier Crashworthiness Studies - a collaborative initiative to examine the effectiveness and safety of pet crates and carriers in the event of a crash. After several eye-opening and informative tests - including instances of complete failure - three top products emerged; CPS has selected the Gunner Kennels G1 Intermediate with 8’ Tie Down Straps as the 2015 Top Performing Crate and both the PetEgo Forma Frame Jet Set Carrier with ISOFIX-Latch Connection and Sleepypod Mobile Pet Bed with PPRS Handilock as the 2015 Top Performing Carriers.
To view the multimedia news release, go to http://www.multivu.com/players/English/7074157-subaru-pet-safety/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Zensun Sci & Tech, Ltd., a biopharmaceutical company based in Shanghai and San Diego, announced today positive results of four completed Phase 2 clinical trials including three double-blind, placebo-controlled studies conducted in China and Australia and interim results from the United States Phase 2 trial for Zensun’s innovative “first-in-class” anti-heart failure drug, Neucardin™.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61677-zensun-completes-clinical-trials-of-neucardin-treatment-of-heart-failure
It won’t cure the common cold, but Appvion, Inc.’s new eco-friendly receipt paper, Alpha Free, proves vitamin C works wonders at the cash register.
Alpha Free is the first and only thermal receipt paper to use a vitamin C formulation in place of phenols like BPA or BPS. Whole Foods Market is now the first major national grocery retailer in America to use the new, natural and sustainable choice in receipt paper that shoppers can feel good about at checkout.
”In the last few years, multiple studies concluded that BPA found in receipts can be absorbed into the skin. If you are someone who handles receipts daily, like a cashier, that can be scary,“ said Dave Pauly, Alpha Free Product Manager for Appvion. ”A growing number of shoppers and employees are looking for more natural product options. That movement encouraged us to develop our vitamin C-based receipt paper, Alpha Free.“
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7541551-appvion-alpha-free-receipts/
A level IV trauma center in Washington State has installed copper components throughout its facility as another way of reducing hospital-acquired infections and keeping their patients safe.
Pullman Regional Hospital has become an early adopter of antimicrobial copper after studies found that the age-old metal could continuously kill deadly bacteria.
Each year, 2 million people in the United States are diagnosed with a hospital-acquired infection and nearly 100,000 people die. These infections are caused by common bacteria such as E. coli, MRSA, C. diff, CRE and VRE.
“It is a very serious problem,” said Ed Harrich, the director of surgical services for Pullman Regional Hospital. “I think every hospital across the nation is doing everything they can to try to deal with it the best that they can. But there’s bioburden on everything and people aren’t good at hand washing and there’s cross-contamination everywhere you go.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7378651-copper-development-association-cda-pullman-regional-hospital-keep-patients-safe-antimicrobial-copper/
Only 3 vehicles of more than 100 evaluated by the Insurance Institute for Highway Safety have child restraint installation hardware that earns a good rating for ease of use, while more than half have hardware that is poor or marginal.
The Institute's new LATCH ratings will serve as a resource for families looking for a vehicle that makes it easy to transport their children safely. They also are intended to encourage vehicle manufacturers to pay attention to this equipment and make improvements. Properly installed, age-appropriate child restraints provide considerably more protection for children in crashes than safety belts alone. However, observational studies have found that parents and caregivers often fail to secure them tightly or make other installation mistakes.
LATCH, which stands for Lower Anchors and Tethers for Children, is intended to make it easier to install a child seat properly. It works: Child restraints installed with LATCH, rather than with vehicle safety belts, are more likely to be installed correctly, research has shown. But in many vehicles, LATCH hardware could be better. Parents are more likely to install the seat correctly when the LATCH hardware meets certain key ease-of-use criteria.
HMR Weight Management Services (HMR), a subsidiary of Merck, has been named a No. 1 Best Fast Weight-Loss Diet in U.S. News & World Report’s Best Diets of 2016 rankings. This is the first year U.S. News has published the Best Fast Weight-Loss Diet category. HMR also held its position as the No. 2 Best Weight-Loss Diet in the annual rankings list for the second year in a row. HMR Programs focus on helping people lose weight quickly while teaching the healthy lifestyle skills needed for long-term weight management.
“HMR programs excel at providing the jump start many people need when beginning a healthier lifestyle program,” said Carol Addy, M.D. MMSc, Chief Medical Officer at HMR. “A common misconception is that losing weight quickly is not healthy, not sustainable, and will just lead to future weight re-gain. To the contrary, numerous clinical studies demonstrate that following a lifestyle change program which promotes fast initial weight loss can result in better long-term success.” Addy added, “On the HMR Program, people can lose weight without feeling hungry. Our programs achieve fast weight loss in a livable way by encouraging people to eat more and stay satisfied, which makes it easier to stick to the program in the short-term, and over the long haul.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7670751-hmr-program-named-best-weight-loss-diet/
GAC Motor’s display of its globalization drive and the latest models at the North American International Auto Show ticked all the right boxes as the leading automotive manufacturer in China built up intimacy with international customers, dealers and business partners.
GAC put its best foot forward in reinforcing its ambitions of making cars for the world as it shed the light on its go–outbound campaign during the international auto exhibition in Detroit that concluded on January 25, 2015.
“After meticulous planning and careful studies, we start to create our own brands by adopting international standards,” said Wu Song, general manager of GAC Motor. “We are confident that GAC Motor can churn out world-class vehicles to compete in the international market.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7447151-gac-motors-detroit-auto-show/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
